Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors

Conditions:   Thyroid Cancer;   Salivary Gland Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Docetaxel
Sponsor:   University of Chicago
Not yet recruiting

http://ift.tt/2iL8qP8